The DZIF Academy is pleased to open the call for application for the fourth DZIF Prize for Translational Infection Research. The German Center for Infection Research (DZIF) will award a prize of 5.000
In 2016, a clinical phase I trial on a potential vaccine against the dreaded Ebola virus was successfully completed. The tested vaccine “rVSV-ZEBOV” proved to be safe and effective. In a further trial
Researchers from the University of Tübingen and the DZIF show medicine is effective when the timing is right. Their new active substance – DSM 265 – demonstrated a good prophylactic effect for Malaria
During pregnancy, a mother’s immune system is suppressed to protect the fetus, which is perceived as a foreign body because it is genetically different. A partly DZIF funded study in mice found that
This year, the Memento Research Award for neglected diseases goes to Dr Carsten Köhler and Prof Peter Kremsner from the Institute of Tropical Diseases at the University Hospital Tübingen. With this
The human immunodeficiency virus has to overcome major obstacles to infect inactive immune cells. DZIF scientists have investigated the defence mechanism of these cells and found indications of a new
Since autumn 2015, the Zika virus epidemic has been causing marked increases in the birth of babies with much too small heads, or so-called “microcephaly”, especially in South and Central America. The
Researchers of the University of Tübingen and DZIF in collaboration with the biotech company Sanaria Inc. have demonstrated in a clinical trial that a new vaccine for malaria called Sanaria® PfSPZ
Almost everybody has it: Scientists estimate that approximately 98 percent of adults around the world are infected with the Epstein-Barr virus. In rare cases, an infection with this virus causes
Severe malaria, caused by the Plasmodium falciparum parasite, causes dangerous circulatory disorders and neurological complications. If the affected person is not treated immediately, the disease will
